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A B S T R A C T
Objective: Bone loss in anorexia nervosa and following bariatric surgery is associated with an elevated circu-
lating concentration of the gastrointestinal, anorexigenic hormone, peptide YY (PYY). Selective deletion of the
PYY receptor Y1R in osteoblasts or Y2R in the hypothalamus results in high bone mass, but deletion of PYY in
mice has resulted in conflicting skeletal phenotypes leading to uncertainty regarding its role in the regulation of
bone mass. As PYY analogs are under development for treatment of obesity, we aimed to clarify the relationship
between PYY and bone mass.
Methods: The skeletal phenotype of Pyy knockout (KO) mice was investigated during growth (postnatal day P14)
and adulthood (P70 and P186) using X-ray microradiography, micro-CT, back-scattered electron scanning
electron microscopy (BSE-SEM), histomorphometry and biomechanical testing.
Results: Bones from juvenile and Pyy KO mice were longer (P < 0.001), with decreased bone mineral content
(P < 0.001). Whereas, bones from adult Pyy KO mice had increased bone mineral content (P < 0.05) with
increased mineralisation of both cortical (P < 0.001) and trabecular (P < 0.001) compartments. Long bones
from adult Pyy KO mice were stronger (maximum load P < 0.001), with increased stiffness (P < 0.01) and
toughness (P < 0.05) compared to wild-type (WT) control mice despite increased cortical vascularity and
porosity (P < 0.001). The increased bone mass and strength in Pyy KO mice resulted from increases in trabe-
cular (P < 0.01) and cortical bone formation (P < 0.05).
Conclusions: These findings demonstrate that PYY acts as a negative regulator of osteoblastic bone formation,
implicating increased PYY levels in the pathogenesis of bone loss during anorexia or following bariatric surgery.
1. Introduction
Bone loss, and increased fracture risk, are features of the metabolic
bone disease caused by caloric restriction or poor nutrition. Decreased
bone mineral density (BMD) and increased susceptibility to fracture
occur in up to 90% of cases of anorexia nervosa, following bariatric
surgery, and in animal models of caloric restriction [1–8].
One potential mechanism for this deterioration in BMD is through
the anti-anabolic actions of peptide YY (PYY). A member of the neu-
ropeptide Y family, PYY is expressed in the brain, gastrointestinal tract
and pancreas, with the highest tissue expression levels in the
neuroendocrine L-cells of the distal gut. PYY has two active forms, the
full length protein PYY(1–36), and the more abundant truncated form,
PYY(3–36) that results from rapid N-terminal cleavage by the ubiqui-
tous protease dipeptidyl peptidase-4 (DPP-4). These PYY peptides cir-
culate in plasma and act through Y receptors, Y1, 2 and 5, to regulate
food intake and beta-cell mass [8–13]. Systemic PYY levels are low in
the fasted state and increase in response to nutrient ingestion
[10,14,15]. Paradoxically, the level of circulating post-prandial PYY is
increased following bariatric surgery, particularly procedures that re-
sult in the rapid delivery of nutrients to L-cells in the ileum and colon
such as Roux-en-Y gastric bypass [16]. The elevated PYY levels
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following bariatric surgery may contribute to reduced appetite and food
intake, as exogenous administration of a PYY(3–36) analogue leads to
reduced food intake in both animal models and human clinical trials
[17–19]. Consequently, PYY analogues are currently under investiga-
tion for the treatment of obesity [20].
An inverse relationship has been reported between circulating PYY
levels and BMD in patients with anorexia nervosa and following bar-
iatric surgery [21,22]. Osteoblast-specific deletion of the Y1 receptor
promoted osteoblast differentiation and mineralisation through in-
creased Runx2 and Osterix expression [23]. Consistent with this, global
Y1R−/− mice have increased BMD and bone mineral content (BMC)
due to increased osteoblastic bone formation and mineral apposition
rates [24]. However, despite the inverse relationship between PYY and
bone density in humans and the high bone mass phenotype observed in
Y1R−/− mice, deletion of PYY in mice has resulted in contrasting
skeletal outcomes [25,26]. In one study, genetic targeting of Pyy re-
sulted in a null allele that retained a lacZ reporter gene and also func-
tionally deleted pancreatic polypeptide. These mice were analysed at
P60 (males), P186 (males), P210 and P275 (males and females) and
displayed decreased BMD and bone volume [25]. In a second study,
gene targeting resulted in retention of Cre recombinase and an EGFP
reporter gene in the knockout allele. By contrast, these mice were
analysed at P98 (males and females) had increased BMD and bone
formation [26]. Overall, these contradictory reports have led to con-
fusion regarding the role of PYY in the regulation of bone mass [25,26].
It is essential to clarify the role of PYY in the regulation of bone
mass and strength because the use of PYY analogues in the treatment of
obesity has the potential to cause long-term detrimental side-effects in
the skeleton, including an increased risk of fracture. We thus de-
termined the skeletal consequences of PYY deletion in Pyy KO mice, in
which gene targeting resulted in a null allele lacking the entire PYY
coding region but retaining only single frt and loxP sites following re-
combination. These mice were studied during skeletal development at
postnatal day 14 and during adulthood at postnatal days 70 and 186 in
both sexes.
2. Materials and methods
2.1. Animals
Global deletion of the Pyy gene in mice was performed using the
Cre-LoxP method as described previously [13]. The resultant global Pyy
KOmice were maintained on a C57BL/6 background. Mice were housed
in a specific pathogen free facility at 22 ± 2 °C with a 12-h light/dark
cycle, and ad libitum access to water and rodent chow. Pyy KOmice and
WT littermate controls were collected at postnatal days P14, P70, P112
and P186, using humane schedule 1 methods. Tissue was collected
immediately and placed in either 70% ethanol or 10% neutral buffered
formalin for 24 h prior to storage in 70% ethanol. All studies were
performed in accordance to the U.K. Animal (Scientific Procedures) Act
1986, the ARRIVE guidelines and the EU Directive 2010/63/EU for
animal experiments.
2.2. Histology – Alcian blue and van Gieson staining of growth plates
Tibias were fixed for 24 h in 10% neutral buffered formalin, dec-
alcified in 10% EDTA, and decalcification confirmed by X-ray micro-
radiography. Samples (n=5 per genotype at P14 and n=4 per sex, per
genotype at P70) were embedded in paraffin and 5 μm sections stained
with Alcian blue and van Gieson [27,28]. Sections were imaged using a
Leica DM LB2 microscope, and measurements taken from at two dif-
ferent levels and a minimum of four positions across the growth plate
using ImageJ to determine mean heights of the growth plate zones [25].
2.3. Osteoclast histomorphometry
Tartrate-resistant acid phosphatase (TRAP) activity was detected in
sections from decalcified paraffin embedded tibias counterstained with
aniline blue (n=2–3 per sex, per genotype at P70) and osteoclast
parameters were determined from two separate levels using a Leica DM
LB2 microscope, as described [29].
2.4. CD31 immunohistochemistry
Platelet endothelial cell adhesion molecule (PECAM-1, CD31) im-
munohistochemistry was performed using sections from decalcified
paraffin embedded tibias (n=4 male Pyy-KO mice at P70). PECAM-1
antigen retrieval was performed in citrate buffer pH 6 at 60 °C for 1 h.
The primary rabbit anti-CD31 antibody ab124432 (Abcam; Cambridge
UK) was diluted 1:500 in. The secondary goat anti-rabbit IgG (horse-
radish peroxidase) antibody ab205718 (Abcam) was diluted 1:1000.
Sections were counterstained with haematoxylin and imaged using a
Leica DM LB2 microscope.
2.5. Digital X-ray microradiography
Femurs and caudal vertebrae 6 and 7 were imaged using an MX20
Faxitron at 26 kV, 10 μm resolution (n=7 per genotype at P14 and
n=7–8 per sex, per genotype at P70 and P186). Steel, aluminium and
polyester standards were used to determine relative bone mineral
content using ImageJ [27,30]. Bone lengths were determined from X-
ray images using ImageJ (n=7 per genotype at P14 and n= 7–8 per
sex, per genotype at P70 and P186).
2.6. Micro-computerised tomography (microCT)
Femur trabecular bone was imaged in 70% ethanol using a Skyscan
1172a micro-computerised tomography scanner (Bruker MicroCT,
Kontich, Belgium) (n=5 per sex, per genotype at P112). Scans were
performed at 50 kV, 200 μA, 0.5 mm aluminium filter with a detection
voxel size of 4 μm3, and images were reconstructed using Skyscan
NRecon software. Trabecular number (Tb.N), thickness (Tb.Th), and
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Fig. 1. Linear growth and endochondral os-
sification.
(A) Femur lengths and caudal vertebral
heights from male and female P14, and male
P70 and P186 WT and Pyy KO mice
(mean ± SEM, n=7–8 per genotype per
age, *P < 0.05, **P < 0.01, ***P < 0.001
versus WT; unpaired t-test).
(B) Decalcified sections of P14 proximal tibia
stained with Alcian blue (cartilage) and van
Gieson (bone matrix); scale bars=100 μm.
Graphs represent the absolute and relative
widths of the resting zone (RZ), proliferating
zone (PZ) and hypertrophic zone (HZ) chon-
drocytes in the growth plate of WT and Pyy
KO mice (mean ± SEM, n=5 per genotype,
*P < 0.05, versus WT; unpaired t-test).
(C) Representative quantitative X-ray micro-
radiographic images of femurs from male and
female P14 and male P70 and P186 WT and
Pyy KO mice; scale bar=1mm. Pseudo-co-
loured images represent grey scale images
using a 16-color interval scheme with low
mineral content blue and high mineral con-
tent pink. Graphs are relative frequency his-
tograms of bone mineral content (BMC)
(n=7–8 per genotype per age, *P < 0.05,
***P < 0.001 versus WT; Kolmogorov-
Smirnov test).
(D) Quantitative X-ray microradiographic
images of vertebrae from male and female
P14 and male P70 and P186 mice; scale
bar=1mm. Relative frequency histograms
of BMC (n=7–8 per genotype per age,
***P < 0.001 versus WT; Kolmogorov-
Smirnov test).
V.D. Leitch, et al. Bone 127 (2019) 427–435
429
bone volume as a proportion of tissue volume (BV/TV) were calculated
within a 1-mm3 region of interest located 0.2mm below the growth
plate [31]. Femur cortical bone was imaged in 70% ethanol using a
Scanco uCT50 (Scanco Medical, Zurich, Switzerland) (n=4–6 per sex,
per genotype at P112). Scans were performed at 70 kV, 200 μA, 0.5 mm
aluminium filter at a 10 μm voxel resolution, and images were re-
constructed using Scanco software. Cortical thickness (Ct.Th), marrow
cavity diameter (Ma.Dm) and cortical bone mineral density (BMD) were
calculated within a 1.5 mm region of interest centered in the mid-shaft
region 56% along the length of the femur distal to the femoral head.
Cortical porosity scans were performed at 1 μm voxel resolution in
0.5 mm3 regions of interest at the mid and distal femur in male mice at
P70 (n=6 per sex, per genotype).
2.7. Back scattered electron scanning electron microscopy (BSE-SEM)
Femurs were fixed in 70% ethanol and then opened longitudinally
using a plain cylinder tungsten carbide burr in a dental hand-piece and
macerated in alkaline bacterial pronase at 55 °C [32]. Samples were
carbon-coated and imaged using back-scattered electrons with a Zeiss
DSM962 digital scanning electron micro-scope at 20-kV beam potential
(KE Electronics) (n=4–5 per sex, per genotype at P70). ImageJ was
used to quantify osteoclastic resorption surfaces as a fraction of total
endosteal and trabecular bone surfaces [27] and to determine endosteal
vascular canal number and size.
2.8. Quantitative BSE-SEM (qBSE-SEM)
Humeri were embedded in polymethyl methacrylate (PMMA), po-
lished to an optically flat finish, carbon coated and imaged by SEM
(Tescan UK, Cambridge, UK) at high vacuum with a 4-quadrant back-
scattered electron detector (Deben, UK) (n=5 per sex, per genotype at
P70 and P186). Images were captured at 20 kV, 0.5 nA at a working
distance of 20mm. Graduations of micro-mineralisation densities were
determined by comparison to high and low molecular weight standards
and visualised using an 8-interval pseudo-color scheme [27,32,33].
2.9. Iodine contrast enhanced BSE-SEM (ICE-BSE-SEM)
Humeri embedded in polymethyl methacrylate (PMMA), were po-
lished to an optically flat finish, and stained with potassium iodide.
Stock Lugol's Iodine solution (Pro-Lab Diagnostics) was diluted with an
equal volume of absolute ethanol and pipetted directly onto the block
surface. After 15min, blocks were washed with distilled water and air
dried. Blocks were imaged by SEM (Tescan UK, Cambridge, UK) at high
vacuum with a 4-quadrant back-scattered electron detector (Deben,
UK) (n=4 per sex, per genotype at P70). Images were captured at
20 kV, 0.6 nA.
2.10. Confocal microscopy
Mice were double calcein labelled with 15mg/kg calcein by intra-
peritoneal injections at seven and three days prior to sacrifice. A Leica
SP2 reflection confocal microscope was used at 488 nm excitation to
image calcein labelling in methacrylate-embedded humeri (n=4–5 per
sex, per genotype at P70). The rate of mineral apposition (MAR) was
determined by calculating the distance separating the two calcein labels
at 20 distinct locations [27,34]. Measurements were performed using
ImageJ.
2.11. Destructive 3-point bend testing
Tibial mechanical strength parameters were determined using
three-point bend testing (n=7–8 per sex, per genotype at P70 and
P186). Destructive 3-point bend tests were performed on an Instron
5543 materials testing load frame using custom built mounts with
rounded supports that minimize cutting and shear loads [27]. Bones
were positioned horizontally and centered on the custom supports with
the anterior surface upward. Load was applied vertically to the mid-
shaft with a constant rate of displacement of 0.03mm/s until fracture.
A span of 12mm was used for all adult tibia and load displacement
curves were used to calculate biomechanical variables [27,35].
2.12. Statistical analysis
Students' t-tests were used to determine the statistical significance of
differences between experimental groups. A P value< 0.05 was con-
sidered significant. Unless stated otherwise, data presented represents
the mean value± standard error. A Kolmogorov-Smirnov test was used
to determine differences between frequency distributions of miner-
alisation densities from qBSE-SEM and digital X-ray microradiography
images and endosteal vessel size from BSE-SEM images [27,28,30].
3. Results
3.1. Linear growth is accelerated but bone mineral content reduced in
juvenile Pyy KO mice
X-ray microradiography analysis demonstrated that male and fe-
male Pyy KO mice had increased femur length and vertebral height at
P14, P70 and P183 (Fig. 1A, Supplementary Fig. 1A). Growth plate
morphology was also abnormal at P14 and characterised by decreased
proliferative zone (PZ) and increased hypertrophic zone (HZ) widths
(Fig. 1B). Nevertheless, growth plate parameters had normalised by P70
(data not shown). Despite increased post-natal linear growth, femurs
and vertebrae from Pyy KO mice had markedly reduced BMC at P14
(Fig. 1C and D).
3.2. Bone mineral content is increased in adult Pyy KO mice
In contrast to the reduced BMC in juvenile Pyy KOmice femurs from
adult Pyy KO mice had increased BMC (Fig. 1C and Supplementary
Fig. 1B). Nevertheless, vertebral BMC was normal in adult Pyy KO mice
(Fig. 1D, Supplementary Fig. 1C).
3.3. Bone mass is increased in adult male Pyy KO mice
At P112 micro-CT analysis demonstrated adult male Pyy KO mice
had increased cortical and trabecular bone mass characterised by in-
creased cortical thickness (C.Th), trabecular bone volume (BV/TV) and
trabecular number (Tb.N) (Fig. 2 A and B). Nevertheless, the cortical
BMD at P112 did not differ from WT (P=0.096) suggesting that the
increase in BMC in early adulthood is a consequence of increased cor-
tical thickness rather than abnormal mineralisation. By contrast, at
P112 cortical and trabecular bone parameters in female Pyy KO mice
were unaffected (Supplementary Fig. 2A and B).
qBSE-SEM analysis demonstrated normal cortical and trabecular
bone mineralisation in male and female Pyy KO at the time of cessation
of linear growth (P70), whereas mineralisation was elevated at both
skeletal sites in males (Fig. 2C and D) and females at P186 (Supple-
mentary Fig. 2C and D).
3.4. Bone formation is increased in Pyy KO mice
To investigate the cellular mechanism underlying the increased
bone mass and mineralisation observed in adult Pyy KO mice, we per-
formed static and dynamic histomorphometry at P70. TRAP staining
revealed no differences in osteoclast number or surface in either male or
female Pyy KO mice compared to WT (Fig. 3A, Supplementary Fig. 3A).
Furthermore, osteoclast endosteal and trabecular resorption surfaces in
male and female Pyy KO mice were similar to WT at P70 (Fig. 3B,
Supplementary Fig. 3B) and P186 (Data not shown). By contrast,
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confocal analysis of calcein double labelling demonstrated increased
mineralising surfaces (MS/BS) and bone formation rates (BFR) in tra-
becular bone and increased MS/BS mineral apposition rate (MAR) and
BFR in cortical bone from male P70 Pyy KO mice (Fig. 3C and D). Bone
formation parameters in female P70 Pyy KO mice were normal (Sup-
plementary Fig. 3C and D).
3.5. Increased bone strength and cortical vascularity in Pyy KO mice
Biomechanical testing revealed increased bone strength and
toughness characterised by increased yield and maximum loads, stiff-
ness and energy dissipated prior to fracture (toughness) in both male
and female P70 Pyy KO mice compared to WT (Fig. 4A, Supplementary
Fig. 4A). In addition to the increase in bone strength and toughness at
P70 in Pyy KO mice, cortical bone vascularity was also increased by
56% in males and by 64% in females (Fig. 4B, Supplementary Fig. 4B).
Nevertheless, the size of these cortical vascular channels did not differ
from WT. Biomechanical testing in older animals demonstrated a per-
sistent increase in bone strength with higher yield, maximum and
fracture loads and stiffness in male Pyy KO mice (Fig. 4C) and higher
maximum and fracture loads in female Pyy KO mice (Supplementary
Fig. 4C). In male P186 Pyy KO mice the number of cortical vascular
canals was similar to WT mice but they were larger in size (Fig. 4D)
whereas, in female P186 Pyy KO mice both the number and size of
cortical vascular channels was increased (Supplementary Fig. 4D).
3.6. Increased cortical porosity in Pyy KO mice
To further investigate the abnormal cortical bone vascularity, we
determined cortical porosity in the mid and distal femur diaphysis in
male P70 Pyy KO mice. Although the mean canal diameter (Ca.Dm) did
not differ between Pyy KO and WT mice, porosity was increased by 61%
in both the mid and distal femur diaphysis in Pyy KO mice compared to
WT (Fig. 5A and B). Importantly, there was no evidence of cortical
trabecularisation of the endosteal surface in male or female mice
(Fig. 3B and 4B and D, Supplementary Fig. 3B and 4 B and D). We used
CD31 (PECAM-1) immunohistochemistry and high resolution iodine
contrast enhanced BSE-SEM to demonstrate that the greater cortical
porosity observed in Pyy KO mice resulted, at least in part, from in-
creased vascularity (Supplementary Fig. S5).
4. Discussion
PYY is a gut hormone secreted from gastrointestinal enteroendo-
crine L-cells in response to nutrient intake [10]. The PYY(3–36) isoform
inhibits appetite and food intake and is currently being evaluated for
Fig. 2. Bone structure and mineralisation.
(A) Transverse micro-CT rendered images of midshaft femur from male P112
WT and Pyy KO mice; scale bar 200 μm. Graphs show cortical bone structural
parameters; cortical thickness (C.Th), marrow cavity diameter (Ma.Dm) and
bone mineral density (BMD) (mean ± SEM, n=4–5 per genotype,
**P < 0.01 versus WT; unpaired t-test).
(B) Representative BSE-SEM images of distal femur trabecular bone from male
P70 WT and Pyy KO mice (n= 4 per genotype); scale bar= 200 μm. Graphs
show trabecular bone structural parameters determined by microCT; bone vo-
lume as a percentage of tissue volume (BV/TV), trabecular number (Tb.N) and
trabecular thickness (Tb.Th) in male P112 WT and Pyy KOmice (mean ± SEM,
n=5 per genotype, *P < 0.05 versus WT; unpaired t-test).
(C) Quantitative BSE-SEM images of cortical bone from the proximal humeri of
male P70 and P186 WT and Pyy KO mice; scale bar= 200 μm. Pseudo-coloured
images represent grey scale images using an 8-color interval scheme with low
mineral content green/yellow and high mineral content pink/grey. Graphs are
relative frequency histograms of bone micro-mineralisation densities (images
representative of n=5 per genotype, ***P < 0.001 versus WT; Kolmogorov-
Smirnov test).
(D) Quantitative BSE-SEM images of trabecular bone from the proximal humeri
of male P70 and P186 WT and Pyy KO mice; scale bar= 200 μm. Relative
frequency histograms of bone micro-mineralisation densities (images re-
presentative of n= 5 per genotype, ***P < 0.001 versus WT; Kolmogorov-
Smirnov test).
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the treatment of obesity [36]. Importantly, the inverse relationship
between circulating PYY and BMD raises the possibility of detrimental
long-term side-effects affecting bone mass and strength in individuals
treated with PYY analogues [21,22]. Here we show that adult Pyy KO
mice have increased bone mass, mineralisation and strength despite
increased cortical bone porosity, demonstrating that PYY is a negative
regulator of adult bone maintenance.
4.1. Clarification of the role of PYY in bone
Previous studies investigating the role of PYY in bone have been
contradictory. Wortley et al. [25] reported decreased bone mineral
content and density in young adult and mature male Pyy KO mice at
P60 and P186, and in both male and female Pyy KO mice at P210
whereas Wong et al. [26] demonstrated increased bone volume, mi-
neral apposition rate and bone formation rate in adult male and female
Pyy KO mice at P98. The current study clarifies this confusion, extends
the findings reported by Wong et al., and is consistent with decreased
bone mass in patients with increased circulating PYY [21,22,26].
The reason for the contrasting phenotypes described in previous
studies [25,26] is unclear, although the different ages of the animals
analysed was raised as a potential confounding factor. To address this
by we analysed mice during growth (P14), at cessation of growth (P70)
and during adulthood (P112 and P186). An alternative explanation for
the divergent skeletal phenotypes observed in previous studies may be
the use of different gene targeting approaches used to delete Pyy.
Wortley et al. [25] replaced the Pyy coding region with a lacZ reporter
gene that is retained in the knockout allele, with mice maintained on a
C57BL/6 background. This approach also resulted in functional dele-
tion of pancreatic polypeptide. By contrast, Wong et al. [26] generated
knockout mice that retained the Cre recombinase gene and an EGFP
reporter in the knockout allele [37]. Here we used Pyy KO mice with
Fig. 3. Osteoclastic bone resorption and osteoblastic bone formation.
(A) Decalcified sections of P70 proximal tibia from male P70 WT and Pyy KO mice stained for tartrate-resistant acid phosphatase (TRAP); scale bar= 200 μm. Black
arrow indicates examples of red TRAP-stained osteoclasts. Graphs show numbers of osteoclasts per mm bone surface (OcN/BS) and osteoclast surface per mm bone
surface (OcS/BS) in male WT and Pyy KO mice (mean ± SEM, n=3 per genotype).
(B) BSE-SEM images of femur endosteal bone surfaces from male P70 WT and Pyy KO mice. Arrows indicate borders between regions of osteoclastic resorption and
unresorbed bone surfaces; scale bar= 200 μm. Graphs show endosteal and trabecular resorption surfaces as percentage of total endosteal and trabecular bone surface
respectively (mean ± SEM, n=4 per genotype).
(C) Confocal images of trabecular bone from proximal humerus of male P70 WT and Pyy KO mice double-labelled with calcein; scale bar= 200 μm. Graphs show
trabecular mineralising surface (MS/BS), mineral apposition rate (MAR) and bone formation rate (BFR) (mean ± SEM, n=5 per genotype, *P < 0.05, **P < 0.01
versus WT; unpaired t-test).
(D) Confocal images of cortical bone from proximal humerus of male mice; scale bar= 200 μm. Graphs show cortical MS/BS, MAR and BFR (mean ± SEM, n=5 per
genotype, *P < 0.05, versus WT; unpaired t-test).
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deletion of the entire coding region but without retention of a selection
marker or expression cassette. These mice were backcrossed and
maintained on a pure C57BL/6 background [13]. Thus the current
study definitively identifies PYY as a negative regulator of bone mass,
mineralisation and strength.
Moreover, the contrasting gene targeting approaches result in con-
trasting secondary metabolic effects, which may also contribute to the
divergent skeletal phenotypes. Wortley et al. [25] reported no change
in food intake, body composition or serum insulin level when Pyy KO
mice were maintained on a standard chow diet. Wong et al. [26],
however, reported sexual dimorphism with increased body weight, re-
duced food intake and increased serum insulin restricted to females
[37]. The Pyy KO mice used in the current study have previously been
shown to exhibit increased food intake, body weight and leptin levels
from 5weeks of age [13]. The potential reasons for the metabolic dif-
ferences between three strains of Pyy KO mice have been discussed in
depth previously [13]. Nevertheless, the similar skeletal abnormalities
reported here and by Wong et al. [26] suggest they are a direct
consequence of deficient PYY signalling in the skeleton rather than
secondary to a systemic metabolic phenotype. Consistent with this, we
show that the underlying cellular mechanism for the increased bone
mass in Pyy KO mice is enhanced osteoblastic bone formation and mi-
neral apposition. Accordingly, increased mineralisation has been re-
ported previously in primary osteoblast cultures obtained from Y2−/−
mice [38] and enhanced ERK signalling has been shown in primary WT
osteoblasts treated with PYY [26,39].
4.2. PYY is a negative regulator of linear growth
Here we show that bone length is increased in juvenile and adult
Pyy KO mice, findings that are consistent with the decreased bone
length previously reported in PYY over-expressing PYYtg mice [26].
These data suggest a novel role for PYY in regulation of endochondral
ossification and linear growth that is supported by the increased hy-
pertrophic differentiation in the growth plates of Pyy KO mice. Of note
and in contrast to the increased bone mass in adult Pyy KO mice,
Fig. 4. Bone strength and cortical vascularity.
(A) Representative load displacement curves from 3-point bend testing of tibias from male P70 WT and Pyy KO mice. Graphs show yield, maximum and fracture
loads, stiffness and energy dissipated prior to fracture (toughness) (mean ± SEM, n=7–8 per genotype, *P < 0.05, **P < 0.01, ***P < 0.001 versus WT;
unpaired t-test).
(B) BSE-SEM images of mid-femur endosteal surfaces from male P70 WT and Pyy KO male mice; scale bar= 200 μm. Graphs show endosteal surface vessel density
and relative frequency histogram of vessel size (mean ± SEM, n=4 per genotype, **P < 0.01 versus WT; unpaired t-test).
(C) Representative load displacement curves from 3-point bend testing of tibias from male P186 WT and Pyy KO mice. Graphs show yield, maximum and fracture
loads, stiffness and energy dissipated prior to fracture (toughness) (mean ± SEM, n= 7–8 per genotype, *P < 0.05, **P < 0.01, versus WT; unpaired t-test).
(D) BSE-SEM images of mid-femur endosteal surfaces from female P186 WT and Pyy KO mice; scale bar= 200 μm. Graphs show endosteal surface vessel density and
relative frequency histogram of vessel size (mean ± SEM, n= 4 per genotype, ***P < 0.001 versus WT; Kolmogorov-Smirnov test).
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juveniles had decreased bone mass indicating bone mineral accrual is
impaired during this period of abnormal linear growth.
4.3. PYY regulates cortical bone vascularity
Increased cortical bone porosity is frequently associated with high
bone turnover osteoporosis and fragility fracture and has been reported
in patients with anorexia nervosa, who have elevated PYY levels
[40,41]. We unexpectedly also demonstrated increased cortical porosity
in adult Pyy KO mice but found it was due to increased vascularity. In
contrast to the cortical porosity, cortical trabecularisation and fragility
seen in high bone turnover osteoporosis, the increased vascularity in
Pyy KO mice at P70 was accompanied by normal bone resorption, in-
creased bone formation, and increased cortical thickness with normal
mineralisation. These increases in bone strength and stiffness at P70
were unexpectedly associated with a marked increase in the energy
dissipated prior to fracture, suggesting that the increased toughness
may result from the abnormal cortical bone porosity. Nevertheless, at
P186 when cortical mineralisation was increased in Pyy KO mice,
toughness did not differ from WT animals indicating that bone strength
and toughness is determined by a complex interplay between cortical
diameter, thickness, mineralisation and porosity. Previous studies have
shown PYY mediates vasoconstriction via Y1 or Y2 receptor [42] con-
sistent with the increased cortical vessel size in P186 Pyy KO mice.
Furthermore, the increase in cortical vessel number in P70 Pyy KO mice
suggests PYY may also inhibit angiogenesis during bone growth.
In conclusion, these data demonstrate PYY is a negative regulator of
adult bone mass and strength and suggest that BMD should be mon-
itored in patients following bariatric surgery or in individuals receiving
PYY analogue treatment.
Acknowledgement
J.H.D.B., A.B., and G.R.W. are funded by a Wellcome Trust Strategic
Award (101123) and J.H.D.B. and G.R.W. by a Wellcome Trust Joint
Investigator Award (110140 and 110141) and a European Commission
Horizon 2020 Grant (666869, THYRAGE). R.L.B holds an NIHR
Research Professorship and is funded by the NIHR, Rosetrees Trust,
Stoneygate Trust, Robert Luff Foundation and Sir Jules Thorn Trust. We
thank Mahrokh Nohadani for invaluable technical support.
Author contributions
R.L.B., G.R.W and J.H.D.B designed experiments, V.D.L., M.J.B.,
S.R., N.C.B., P.M., J.G.L., A.B., H.E., G.R.W. and J.H.D.B. performed
experiments, V.D.L., M.J.B., S.R., N.C.B., P.M., J.G.L., A.B., H.E., P.I.C.,
G.R.W., and J.H.D.B. analysed data, V.D.L., G.R.W., and J.H.D.B. wrote
the manuscript, V.D.L., N.C.B., J.G.L., A.B., P.I.C., R.L.B., G.R.W., and
J.H.D.B. revised the final paper version. All authors reviewed the results
and approved the final version of the manuscript.
Declarations of interest
None
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bone.2019.07.011.
References
[1] S. Grinspoon, E. Thomas, S. Pitts, E. Gross, D. Mickley, K. Miller, et al., Prevalence
and predictive factors for regional osteopenia in women with anorexia nervosa,
Ann. Intern. Med. 133 (10) (2000) 790–794.
[2] K.K. Miller, S.K. Grinspoon, J. Ciampa, J. Hier, D. Herzog, A. Klibanski, Medical
findings in outpatients with anorexia nervosa, Arch. Intern. Med. 165 (5) (2005)
561–566.
[3] J. Fleischer, E.M. Stein, M. Bessler, M. Della Badia, N. Restuccia, L. Olivero-Rivera,
et al., The decline in hip bone density after gastric bypass surgery is associated with
extent of weight loss, J. Clin. Endocrinol. Metab. 93 (10) (2008) 3735–3740.
[4] M.J. Devlin, A.M. Cloutier, N.A. Thoman, D.A. Panus, S. Lotinun, I. Pinz, et al.,
Caloric restriction leads to high marrow adiposity and low bone mass in growing
mice, J. Bone Miner. Res. 25 (9) (2010) 2078–2088.
[5] E.W. Yu, Bone metabolism after bariatric surgery, J. Bone Miner. Res. 29 (7) (2014)
1507–1518.
[6] A.K. Behrendt, A. Kuhla, A. Osterberg, C. Polley, P. Herlyn, D.C. Fischer, et al.,
Dietary restriction-induced alterations in bone phenotype: effects of lifelong versus
short-term caloric restriction on femoral and vertebral bone in C57BL/6 mice, J.
Bone Miner. Res. 31 (4) (2016) 852–863.
[7] K.F. Axelsson, M. Werling, B. Eliasson, E. Szabo, I. Naslund, H. Wedel, et al.,
Fracture risk after gastric bypass surgery: a retrospective cohort study, J. Bone
Miner. Res. 33 (12) (2018) 2122–2131.
Fig. 5. Cortical porosity.
(A) Transverse and anterior-posterior micro-CT images showing cortical bone porosity in the mid-femoral diaphysis of male P70 Pyy KO and WT mice;
bars= 200 μm. Graphs show mean canal diameter (Ca.Dm) and cortical porosity (Ct.Po) (Pore volume/Cortical bone volume (Po·V/Ct.V)) (mean ± SEM, n=6 per
genotype, **P < 0.01 versus WT; unpaired t-test).
(B) Micro-CT images showing cortical bone porosity in distal-femoral diaphysis of male P70 Pyy KO and WT mice; bars= 200 μm. Graphs show mean canal diameter
(Ca.Dm) and cortical porosity (Ct.Po) (mean ± SEM, n= 6 per genotype, ***P < 0.001 versus WT; unpaired t-test).
V.D. Leitch, et al. Bone 127 (2019) 427–435
434
[8] Fazeli, P.K., Klibanski, A., 2018. Effects of anorexia nervosa on bone metabolism.
Endocr. Rev. 39(6): 985–910.
[9] K. Tatemoto, V. Mutt, Isolation of two novel candidate hormones using a chemical
method for finding naturally occurring polypeptides, Nature 285 (5764) (1980)
417–418.
[10] T.E. Adrian, G.L. Ferri, A.J. Bacarese-Hamilton, H.S. Fuessl, J.M. Polak, S.R. Bloom,
Human distribution and release of a putative new gut hormone, peptide YY,
Gastroenterology 89 (5) (1985) 1070–1077.
[11] E. Ekblad, F. Sundler, Distribution of pancreatic polypeptide and peptide YY,
Peptides 23 (2) (2002) 251–261.
[12] R.L. Batterham, M.A. Cowley, C.J. Small, H. Herzog, M.A. Cohen, C.L. Dakin, et al.,
Gut hormone PYY(3-36) physiologically inhibits food intake, Nature 418 (6898)
(2002) 650–654.
[13] R.L. Batterham, H. Heffron, S. Kapoor, J.E. Chivers, K. Chandarana, H. Herzog,
et al., Critical role for peptide YY in protein-mediated satiation and body-weight
regulation, Cell Metab. 4 (3) (2006) 223–233.
[14] F. Witjaksono, W. Lukito, A. Wijaya, N.G. Annisa, J. Jutamulia, F. Nurwidya, et al.,
The effect of breakfast with different macronutrient composition on PYY, ghrelin,
and ad libitum intake 4 h after breakfast in Indonesian obese women, BMC Research
Notes 11 (1) (2018) 787.
[15] R.L. Batterham, M.A. Cohen, S.M. Ellis, C.W. Le Roux, D.J. Withers, G.S. Frost,
et al., Inhibition of food intake in obese subjects by peptide YY3-36, N. Engl. J. Med.
349 (2003) 941–948.
[16] P.J. Yang, M.F. Cheng, W.S. Yang, M.S. Tsai, P.C. Lee, C.N. Chen, et al., A higher
preoperative glycemic profile is associated with rapid gastric emptying after sleeve
gastrectomy for obese subjects, Obes. Surg. 29 (2) (2019) 569–579.
[17] K. Chandarana, C. Gelegen, E. Karra, A.I. Choudhury, M.E. Drew, V. Fauveau, et al.,
Diet and gastrointestinal bypass-induced weight loss: the roles of ghrelin and
peptide YY, Diabetes 60 (3) (2011) 810–818.
[18] N. Nishizawa, A. Niida, Y. Adachi, Y. Kanematsu-Yamaki, Y. Masuda, S. Kumano,
et al., Highly potent antiobesity effect of a short-length peptide YY analog in mice,
Bioorganic and Medicinal Chemistry 25 (20) (2017) 5718–5725.
[19] T. Tan, P. Behary, G. Tharakan, J. Minnion, W. Al-Najim, N.J.W. Albrechtsen, et al.,
The effect of a subcutaneous infusion of GLP-1, OXM, and PYY on energy intake and
expenditure in obese volunteers, Journal of Endocrinology and Metabolism 102 (7)
(2017) 2364–2372.
[20] B.T. Meneguetti, M.H. Cardoso, C.F. Acosta Ribeiro, M.R. Felicio, I.B. Pinto,
N.C. Santos, et al., Neuropeptide receptors as potential pharmacological targets for
obesity, Pharmacol. Ther. S0163–7258 (18) (2018) 30199–30202.
[21] A.L. Utz, E.A. Lawson, M. Misra, D. Mickley, S. Gleysteen, D.B. Herzog, et al.,
Peptide YY (PYY) levels and bone mineral density (BMD) in women with anorexia
nervosa, Bone 43 (1) (2008) 135–139.
[22] E.W. Yu, M. Wewalka, S.A. Ding, D.C. Simonson, K. Foster, J.J. Holst, et al., Effects
of gastric bypass and gastric banding on bone remodeling in obese patients with
type 2 diabetes, J. Clin. Endocrinol. Metab. 101 (2) (2016) 714–722.
[23] M. Yahara, K. Tei, M. Tamura, Inhibition of neuropeptide Y Y1 receptor induces
osteoblast differentiation in MC3T3-E1 cells, Mol. Med. Rep. 16 (3) (2017)
2779–2784.
[24] P.A. Baldock, S.J. Allison, P. Lundberg, N.J. Lee, K. Slack, E.J.D. Lin, et al., Novel
role of Y1 receptors in the coordinated regulation of bone and energy homeostasis,
J. Biol. Chem. 282 (26) (2007) 19092–19102.
[25] K.E. Wortley, K. Garcia, H. Okamoto, K. Thabet, K.D. Anderson, V. Shen, et al.,
Peptide YY regulates bone turnover in rodents, Gastroenterology 133 (5) (2007)
1534–1543.
[26] I.P. Wong, F. Driessler, E.C. Khor, Y.C. Shi, B. Hormer, A.D. Nguyen, et al., Peptide
YY regulates bone remodeling in mice: a link between gut and skeletal biology,
PLoS One 7 (7) (2012) e40038.
[27] J.H.D. Bassett, A. Boyde, P.G. Howell, R.H. Bassett, T.M. Galliford, M. Archanco,
et al., Optimal bone strength and mineralization requires the type 2 iodothyronine
deiodinase in osteoblasts, Proc. Natl. Acad. Sci. 107 (16) (2010) 7604–7609.
[28] J.H.D. Bassett, J.G. Logan, A. Boyde, M.S. Cheung, H. Evans, P.I. Croucher, et al.,
Mice lacking the calcineurin inhibitor Rcan2 have an isolated defect of osteoblast
function, Endocrinology 153 (7) (2012) 3537–3548.
[29] J.H.D. Bassett, A.H. Van der Spek, J.G. Logan, A. Gogakos, J. Bagchi-Chakraborty,
E. Murphy, et al., Thyrostimulin regulates osteoblastic bone formation during early
skeletal development, Endocrinology 156 (9) (2015) 3098–3113.
[30] J.H.D. Bassett, A.H. Van der Spek, A. Gogakos, G.R. Williams, Quantitive x-ray
imagining of rodent bone by faxitron, in: M.H. Helfrich, S.H. Ralston (Eds.), Bone
Research Protocols, Humana Press, 2012, pp. 499–506.
[31] V.D. Leitch, C. Di Cosmo, X.H. Liao, S. O'Boy, T.M. Galliford, H. Evans, et al., An
essential physiological role for MCT8 in bone in male mice, Endocrinology 158 (9)
(2017) 3055–3066.
[32] J.H.D. Bassett, K. Nordstrom, A. Boyde, P.G. Howell, S. Kelly, B. Vennstrom, et al.,
Thyroid status during skeletal development determines adult bone structure and
mineralization, Mol. Endocrinol. 21 (2007) 1893–1904.
[33] A. Boyde, R. Travers, F.H. Glorieux, S.J. Jones, The mineralization density of iliac
crest bone from children with osteogenesis imperfecta, Calcif. Tissue Int. 64 (3)
(1999) 185–190.
[34] M. Doube, E.C. Firth, A. Boyde, Variations in articular calcified cartilage by site and
exercise in the 18-month-old equine distal metacarpal condyle, Osteoarthr. Cartil.
15 (11) (2007) 1283–1292.
[35] J.L. Schriefer, A.G. Robling, S.J. Warden, A.J. Fournier, J.J. Mason, C.H. Turner, A
comparison of mechanical properties derived from multiple skeletal sites in mice, J.
Biomech. 38 (3) (2005) 467–475.
[36] S. Price, S.R. Bloom, Protein PYY and its role in metabolism, Frontiers in Hormone
Research 42 (2014) 147–154.
[37] D. Boey, S. Lin, T. Karl, P.A. Baldock, N. Lee, R. Enriquez, et al., Peptide YY ablation
in mice leads to the development of hyperinsulinaemia and obesity, Diabetologica
49 (6) (2006) 1360–1370.
[38] P. Lundberg, S.J. Allison, N. Lee, P.A. Baldock, N. Brouard, S. Rost, et al., Greater
bone formation of Y2 knockout mice is associated with increased osteoprogenitor
numbers and altered Y1-receptor expression, J. Biol. Chem. 282 (2007)
19082–19091.
[39] N.J. Lee, K.L. Doyle, A. Sainsbury, R. Enriquez, Y.J. Hort, S.J. Riepler, et al., Critical
role for Y1 receptors in mesenchymal progenitor cell differentiation and osteoblast
activity, J. Bone Miner. Res. 25 (8) (2010) 1736–1747.
[40] A.T. Faje, L. Karim, A. Taylor, H. Lee, K.K. Miller, N. Mendes, et al., Adolescent girls
with anorexia nervosa have impaired cortical and trabecular microarchitecture and
lower estimated bone strength at the distal radius, J. Clin. Endocrinol. Metab. 98 (5)
(2013) 1923–1929.
[41] V. Singhal, S. Tulsiani, K.J. Campoverde, D.M. Mitchell, M. Slattery, M. Schorr,
et al., Impaired bone strength estimates at the distal tibia and its determinants in
adolescents with anorexia nervosa, Bone 106 (2018) 61–68.
[42] R.M. Smith, R. Klein, P. Kruzliak, A. Zulli, Role of peptide YY in blood vessel
function and atherosclerosis in a rabbit model, Clin. Exp. Pharmacol. Physiol. 42 (6)
(2015) 648–652.
V.D. Leitch, et al. Bone 127 (2019) 427–435
435
